Logo

PGEN

Precigen, Inc.

PGEN

Precigen, Inc. • NASDAQ
$3.83 ▲ 2.41% (+0.09)
Market Cap $1.15 B
52w High $5.23
52w Low $0.65
Dividend Yield 0%
P/E -2.7
Volume 1.78M
Outstanding Shares 300.43M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.922M ▲ $36.368M ▲ $-146.344M ▼ -5.008K% ▼ $-1.1 ▼ $-144.639M ▼
Q2-2025 $856K ▼ $31.065M ▲ $-26.642M ▲ -3.112K% ▲ $-0.09 ▲ $-27.227M ▲
Q1-2025 $1.341M ▲ $22.837M ▼ $-54.153M ▼ -4.038K% ▼ $-0.18 ▼ $-53.523M ▼
Q4-2024 $1.19M ▲ $28.537M ▲ $-19.727M ▲ -1.658K% ▲ $-0.067 ▲ $-19.153M ▲
Q3-2024 $953K $21.206M $-23.978M -2.516K% $-0.087 $-23.29M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $121.135M ▲ $171.264M ▲ $129.396M ▼ $41.868M ▲
Q2-2025 $59.753M ▼ $101.896M ▼ $138.675M ▼ $-36.779M ▼
Q1-2025 $80.242M ▼ $128.787M ▼ $142.847M ▲ $-14.06M ▼
Q4-2024 $97.91M ▲ $145.266M ▲ $106.753M ▲ $38.513M ▼
Q3-2024 $28.631M $83.474M $28.098M $55.376M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-146.344M ▼ $-29.069M ▼ $-63.386M ▼ $93.007M ▲ $562K ▼ $-29.458M ▼
Q2-2025 $-26.642M ▲ $-18.977M ▼ $28.442M ▲ $-1.766M ▼ $7.702M ▲ $-19.943M ▼
Q1-2025 $-54.153M ▼ $-16.325M ▼ $-6.457M ▲ $-679K ▼ $-23.459M ▼ $-16.947M ▼
Q4-2024 $-19.727M ▲ $-8.243M ▲ $-65.367M ▼ $78.404M ▲ $4.792M ▼ $-9.271M ▲
Q3-2024 $-23.978M $-22.733M $5.653M $32.127M $15.117M $-23.615M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Operating Segments
Operating Segments
 $0 ▲$0 ▲$0 ▲$0 ▲
Biopharmaceuticals Segment
Biopharmaceuticals Segment
 $0 ▲$0 ▲$0 ▲$0 ▲
Exemplar Segment
Exemplar Segment
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Precigen is still very much a research‑stage company: revenue is tiny and has even trended down, so the business is not yet supported by product sales. Operating results show recurring losses each year, reflecting heavy spending on R&D and overhead without offsetting commercial income. Profitability briefly improved a few years ago, likely helped by one‑time items, but has since reverted to losses. Per‑share results remain negative, which is typical for a small biotech before its first approval but highlights ongoing dependence on external funding rather than internal profits.

Balance Sheet

Balance Sheet The balance sheet has gradually slimmed down, with total assets now meaningfully lower than a few years ago. Cash is modest and, while not zero, does not look abundant for a company still in clinical development. On the positive side, debt has been reduced to relatively low levels, which limits financial leverage risk. Equity remains positive but has not grown, reflecting cumulative losses; overall, the company appears financially lean and reliant on future fundraising, partnerships, or a successful product launch to reinforce its capital base.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, showing a steady burn to fund trials and platform development. Capital spending is quite modest, so almost all cash outflow is tied to running the business and R&D rather than big physical investments. Free cash flow has therefore been negative year after year, though the size of the burn has been relatively stable rather than rapidly escalating. This pattern is typical for a clinical‑stage biotech but means Precigen’s future flexibility depends heavily on access to capital markets or upfront payments from partners.

Competitive Edge

Competitive Edge Competitively, Precigen has carved out a differentiated position in gene and cell therapy with its fast‑manufacturing UltraCAR‑T platform and its AdenoVerse viral vector technology. The potential first‑in‑class therapy for Recurrent Respiratory Papillomatosis could give it a strong early foothold in a niche area with high unmet need. A sizable patent portfolio and proprietary manufacturing tools support its technological moat. At the same time, the company remains small and pre‑commercial in a field dominated by larger, well‑funded players, and has already had to narrow its focus and pause some programs, underscoring both its resource constraints and its dependence on a few key assets and regulatory outcomes.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here: Precigen controls multiple advanced platforms, including UltraCAR‑T and AdenoVerse, with meaningful scientific differentiation such as non‑viral gene delivery, multigenic cell engineering, and repeatable viral dosing. Management has recently refocused R&D around the most advanced program, PRGN‑2012 for RRP, and a smaller number of priority assets, while winding down or pausing others like the ActoBiotics platform and some UltraCAR‑T trials. Collaboration with the National Cancer Institute on HPV‑related cancers adds external scientific validation. The trade‑off is that the pipeline is now more concentrated, increasing the impact of success or failure in a handful of programs rather than a broad spread of shots on goal.

Summary

Overall, Precigen looks like a science‑rich but financially lean biotech at an inflection point. The company’s income statement and cash flows show a classic pre‑revenue profile: recurring losses and steady cash burn with minimal sales. The balance sheet has been trimmed and de‑levered, which reduces debt risk but also highlights limited resources. Strategically, the story now centers on potential approval and launch of PRGN‑2012 and on monetizing its platforms through partnerships. Future progress will likely hinge on clinical and regulatory outcomes, execution of a first commercial launch, and the ability to secure supportive financing or collaborations in a highly competitive therapeutic area.

NEWS

November 13, 2025 · 4:05 PM UTC

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Read more

November 6, 2025 · 4:30 PM UTC

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Read more

October 13, 2025 · 7:00 AM UTC

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Read more

September 3, 2025 · 7:00 AM UTC

Precigen Announces Up to $125 Million Non-Dilutive Financing

Read more